Feb 21 2020
Hepatocellular carcinoma (HCC) is one of the liver cancer and related to the various liver diseases. Since the tumor is consist of the highly heterogeneous tumor cells and conventional therapies show insufficient efficacy, a development of the new therapeutic options is an unmet clinical needs.
Senior Lecturer Kenya Kamimura, Professor Shuji Terai, and their research group at the Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences has developed a novel toxin-based gene therapy for HCC and demonstrated its effectiveness and safety in a joint study with Professor Hiroshi Nishina and colleagues at the Department of Developmental and Regenerative Biology, Medical Research Institute of Tokyo Medical and Dental University, and Professor Masato Ohtsuka and colleagues at the Department of Molecular Life Sciences, Division of Basic Medical Science and Molecular Medicine, Tokai University School of Medicine.
Title:?Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma
Journal:?Cancers
Authors:?Kenya Kamimura*, Takeshi Yokoo, Hiroyuki Abe, Norihiro Sakai, Takuro Nagoya, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Akira Sakamaki, Hiroteru Kamimura, Norio Miyamura, Hiroshi Nishina, Shuji Terai
*: corresponding author
Increasing trend of overweight and obesity among Japanese patients with incident end-stage kidney disease
Verifying the Effect to Enhance Swallowing Initiation of Crystalline Oil and Fat: Expected to Develop Dysphagia Diet for Patients with dysphagia
Discovery of Glass-Forming Liquid Electrolytes as a New Liquid Category: Specific Lithium-Ion Conduction and Assignment of Key Dissolved Chemical Species